FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

4 results

bkemv
(eculizumab-aeeb)
Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. It is not for Shiga toxin E. coli related HUS.
epysqli
(Eculizumab-aagh)
Teva Pharmaceuticals USA, Inc.
Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. Not for STEC-HUS.
soliris
(ECULIZUMAB)
Alexion Pharmaceuticals Inc.
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.
ultomiris
(ravulizumab)
Alexion Pharmaceuticals Inc.
Usage: ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.

Medications for Atypical Hemolytic Uremic Syndrome

bkemv

epysqli

soliris

ultomiris